Ovid Therapeutics Inc (OVID)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $479.38M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ovid Therapeutics Inc (OVID) Stock Forecast
Analysts expect Ovid Therapeutics (OVID) to earn -$0.40 per share in the fiscal year ending Dec 31, 2026, on revenue of $788250. Of 13 analysts, 13 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 7 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 13 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus is unchanged and revenue estimates fall 77.8%.
- Fiscal year ending Dec 31, 2026
- -$0.40
- EPS consensus, revenue $788250
- Fiscal year ending Dec 31, 2027
- -$0.40
- EPS consensus, revenue $175080
- Next report
- Mar 16, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.40 | -$0.45 to -$0.36 | 9 | $788250 | $700000 to $1.45M | 12 |
| Dec 31, 2027 | -$0.40 | -$0.50 to -$0.29 | 9 | $175080 | N/A | 12 |
Quarterly Estimates
The EPS consensus is -$0.10 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.10 | -$0.14 to -$0.08 | 14 | $83895 | N/A | 15 |
| Mar 31, 2027 | -$0.10 | -$0.11 to -$0.08 | 4 | $20000 | N/A | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 13 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 7 | 0 |
| Fiscal year ending Dec 31, 2027 | 4 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.44.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.40 | -$0.36 | -$0.38 | -$0.37 | -$0.44 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.40 | -$0.37 | -$0.38 | -$0.39 | -$0.44 | N/A |
| Quarter ending Mar 31, 2027 | -$0.10 | -$0.09 | -$0.09 | -$0.09 | -$0.11 | N/A |
Frequently Asked Questions About OVID
What is the OVID stock forecast?
Consensus analyst estimates put Ovid Therapeutics's EPS at -$0.40 for the fiscal year ending Dec 31, 2026, on revenue of $788250. The consensus rating from 13 analysts is Buy.
How do analysts rate OVID stock?
Of 13 analysts covering Ovid Therapeutics, 0 rate it Strong Buy, 13 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from OVID next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.40, with estimates from -$0.45 to -$0.36 from 9 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.40, with estimates from -$0.50 to -$0.29 from 9 analysts.
What revenue do analysts expect from Ovid Therapeutics next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $788250, with estimates from $700000 to $1.45M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $175080.
How many analysts cover OVID?
13 analysts rate Ovid Therapeutics stock, and 9 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
OVID pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors